|
|
|
| Clinical effect of Calcitriol in the treatment of Hashimoto thyroiditis |
| SUN Chuang |
| Department of Endocrinology,Xincheng Hospital of Liaoyang Central Hospital |
|
|
|
|
Abstract Objective To explore the clinical effect of Calcitriol in the treatment of Hashimoto thyroiditis.Methods A total of 110 patients with Hashimoto thyroiditis treared in Xincheng Hospital of Liaoyang Central Hospital selected from January 2019 to January 2021 were selected and divided into the control group and the observation group according to random number table method,with 55 cases in each group.The control group was treated with Levothyroxine Tablets,and the observation group was treated with Calcitriol on the basis of the control group.The clinical efficacy,thyroid hormone indexes,concentration of anti-thyroglobulin antibody (TGAb) and anti-thyroid peroxidase antibody (TPOAb)before and after treatment were compared between the two groups,and the adverse reactions during treatment were observed.Results The total clinical effective rate of the observation group was higher than that of the control group,the difference was statistically significant (P＜0.05).The levels of free triiodothyronine (FT3) and free thyroxine (FT4) in the observation group after treatment were higher than those in the control group,and the levels of thyroid stimulating hormone (TSH),TGAb and TPOAb in the observation group after treatment were lower than those in the control group,the differences were statistically significant (P＜0.05).During the treatment period,there were no adverse reactions such as blood routine,urine routine,liver and kidney function index lesions in the two groups.Conclusion The addition of Calcitriol on the basis of Levothyroxine Tablets in the treatment of Hashimoto thyroiditis can achieve significant clinical effects,can promote the improvement of thyroid hormone levels,adjust the concentration of TGAb and TPOAb,and there is no obvious adverse reaction during the treatment period,with high safety.
|
|
|
|
|
|
| [1] |
高绪文，李继莲.甲状腺疾病[M].北京：人民卫生出版社，1999：190-193.
|
| [2] |
傅莉萍，金剑虹，王保法，等.骨化三醇对桥本甲状腺炎患者TPOAb、TgAb、Th17/Treg 相关细胞因子的影响[J].浙江医学，2019，41（22）：2398-2401.
|
| [3] |
中华医学会内分泌学分会中国甲状腺疾病诊治指南编写组.中国甲状腺疾病诊治指南[J].中华内科杂志，2008，47（9）：784-788.
|
| [4] |
杨雪威，王思源，赵佳，等.骨化三醇对桥本甲状腺炎大鼠血清炎性细胞因子表达的影响及其意义[J].东南大学学报（医学版），2018，37（5）：904-908.
|
| [5] |
董笑克，洪明昭，韩艺凡，等.骨化三醇对自身免疫性甲状腺炎大鼠T 淋巴细胞亚群的影响[J].现代生物医学进展，2017，17（30）：5818-5822.
|
| [6] |
Esfahanian F，Ghelich R，Rashidian H，et al.Increased levels of serum interleukin-17 in patients with hashimoto′s thyroiditis[J].Indian J Endocrinol Metab，2017，21（4）：551-554.
|
| [7] |
闵亚丽，晏晓英，李晓颖，等.小剂量西那卡塞联用骨化三醇治疗维持性血透继发性甲旁亢患者的疗效观察及对FGF23/Klotho 轴的影响[J].中国处方药，2019，17（6）：110-112.
|
| [8] |
Okuroglu N，Ozdemir A，Sertbas Y，et al.The relationship between thyroid antibody titer and levothyroxine dose in patients with overt primary hypothyroidism[J].Ann Saudi Med，2017，37（3）：189-193.
|
| [9] |
鹿冬梅，杨沿浪，王金宝，等.西那卡塞联合骨化三醇对MHD 尿毒症继发甲状旁腺功能亢进患者矿物质及骨代谢的影响[J].贵州医科大学学报，2019，44（8）：965-970.
|
| [10] |
王辉，王云.骨化三醇联合西那卡塞治疗血液透析患者继发性甲状旁腺功能亢进的疗效[J].中国血液净化，2019，18（1）：8-11.
|
| [11] |
孙中.前列地尔联合骨化三醇治疗慢性肾衰竭的疗效及对血清ANG Ⅱ、MCP-1、CTGF 的影响[J].空军医学杂志，2019，35（5）：429-431.
|
| [12] |
谭菲，舒峤.骨化三醇联合碳酸司维拉姆治疗终末期肾脏病合并甲状旁腺功能亢进症患者的效果及对hs-CRP、FGF-23 水平的影响[J].中国医学创新，2019，16（2）：109-112.
|
| [13] |
张红涛.骨化三醇对桥本甲状腺炎甲状腺功能减退症患者FT3、FT4、TGAb、TPOAb 水平的影响[J].中国现代医药杂志，2020，22（6）：27-28.
|
| [14] |
Legarth C，Grimm D，Wehland M，et al.The impact of vitamin D in the treatment of essential hypertension[J].Int J Mol Sci，2018，19（2）：455-456.
|
| [15] |
牛晓暐.二仙消瘿汤联合131I 治疗桥本甲状腺炎对TgAb、TPOAb 浓度的影响[J].四川中医，2020，38（11）：147-148.
|
|
|
|
